Efficacy of subsequent-abemaciclib treatment after disease progression on palbociclib combined with endocrine therapy in patients with ER-positive HER2-negative metastatic breast cancer

被引：0
|
作者：
Seki, Hirohito
Nakai, Taketo
Shimizu, Ken
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P5-02-49
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-02-49
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Liquid Biopsy Testing in a Greek Cohort of ER-positive, HER2-negative metastatic breast cancer patients
    Tsoulos, Nikolaos
    Meintani, Angeliki
    Kapetsis, Georgios
    Chatzigiannidou-Florou, Chrysiis
    Tsantikidi, Aikaterini
    Maxouri, Stella
    Thanou, Eleni
    Aggelaina, Kalliopi
    Metaxa-Mariatou, Vasiliki
    Tsaousis, Georgios
    Natsiopoulos, Ioannis
    Venizelos, Vasileios
    Markopoulos, Christos
    Zagouri, Flora
    Kampletsas, Eleftherios
    Karyda, Eirini
    Tryfonopoulos, Dimitrios
    Papazisis, Konstantinos
    Ziogas, Dimitrios
    Athanasiadis, Ilias
    Papadopoulou, Eirini
    Nasioulas, Georgios
    CANCER RESEARCH, 2024, 84 (09)
  • [22] Profiling the early haematological dynamics and treatment modifications with palbociclib when used as first line treatment for ER-positive, HER2-negative metastatic breast cancer
    Bhojwani, A.
    Flint, H.
    Hall, B.
    Wong, H.
    Innes, H.
    Cliff, J.
    Ahmed, E.
    Malik, Z.
    O'Hagan, J.
    Tolan, S.
    Hall, A.
    Hyatt, K.
    Errington, D.
    Alam, F.
    Robson, P.
    Thorp, N.
    O'Reilly, S.
    Law, A.
    Cicconi, S.
    Jackson, R.
    Palmieri, C.
    CANCER RESEARCH, 2019, 79 (04)
  • [23] Comparison of Safety and Treatment Continuity of Palbociclib and Abemaciclib for Hormone Receptor-Positive, HER2-Negative Metastatic/Recurrent Breast Cancer
    Go, Makiko
    Kimura, Michio
    Yamada, Shiori
    Usami, Eiseki
    Noguchi, Yoshihiro
    Yoshimura, Tomoaki
    JOURNAL OF PHARMACY PRACTICE, 2024, 37 (06) : 1258 - 1266
  • [24] Palbociclib for the Treatment of Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
    Morikawa, Aki
    Henry, N. Lynn
    CLINICAL CANCER RESEARCH, 2015, 21 (16) : 3591 - 3596
  • [25] The SMILE Study: A phase II trial of onapristone in combination with fulvestrant for patients with ER-positive and HER2-negative metastatic breast cancer after progression on endocrine therapy and CDK 4/6 inhibitors
    Kamaraju, Sailaja
    Fowler, Amy
    Chaudhary, Lubna N.
    Burkard, Mark
    Giever, Thomas
    Hegeman, Robert N.
    Pipp-Dahm, Michele
    Cheng, Yee Chung
    Lange, Carol
    Jorns, Julie M.
    Stella, Amy
    Siddiqui, Nauman
    Zurbriggen, Luke
    Rajguru, Saurabh
    Tarima, Sergey
    Sriram, Deepika
    Retseck, Janet
    Rui, Hallgeir
    Sahmoud, Tarek
    Wisinski, Kari B.
    CANCER RESEARCH, 2023, 83 (05)
  • [26] Challenges in the management of advanced, ER-positive, HER2-negative breast cancer
    Christopher D. Hart
    Ilenia Migliaccio
    Luca Malorni
    Cristina Guarducci
    Laura Biganzoli
    Angelo Di Leo
    Nature Reviews Clinical Oncology, 2015, 12 : 541 - 552
  • [27] A retrospective study of 27 patients with ER-positive, HER2 negative metastatic breast cancer treated with concomitant palbociclib and radiation therapy
    Beddok, Arnaud
    Arsene-Henry, Alexandre
    Porte, Baptiste
    Cao, Kim
    Bazire, Louis
    Scher, Nathaniel
    Labib, Alain
    Darmon, Ilan
    Otz, Joelle
    Minsat, Mathieu
    Mammar, Hamid
    Bidar, Francois Clement
    Fourquet, Alain
    Cottu, Paul
    Poortmans, Phlip
    Kirova, Youlia
    CANCER RESEARCH, 2020, 80 (04)
  • [28] Efficacy, safety, and predictive model of Palbociclib in the treatment of HR-positive and HER2-negative metastatic breast cancer
    Wang, Wei
    Lei, Wenqian
    Fang, Ziru
    Jiang, Ruiyuan
    Wang, Xiaojia
    BMC CANCER, 2024, 24 (01)
  • [29] Challenges in the management of advanced, ER-positive, HER2-negative breast cancer
    Hart, Christopher D.
    Migliaccio, Ilenia
    Malorni, Luca
    Guarducci, Cristina
    Biganzoli, Laura
    Di Leo, Angelo
    NATURE REVIEWS CLINICAL ONCOLOGY, 2015, 12 (09) : 541 - 552
  • [30] Efficacy, safety, and predictive model of Palbociclib in the treatment of HR-positive and HER2-negative metastatic breast cancer
    Wei Wang
    Wenqian Lei
    Ziru Fang
    Ruiyuan Jiang
    Xiaojia Wang
    BMC Cancer, 24
12345